Gone Vegan.
Capsugel® HPMC portfolio

Contact us: solutions.emea@lonza.com  |   www.capsugel.com

Non-animal based alternative   |   Broadest HPMC offering  |  Capsugel® quality and performance

Lonza makes no warranties or representations of accuracy or completeness. All trademarks belong to Lonza or its affiliates.

Vcaps® Plus

The gold standard in HPMC capsules

Properties

  • HPMC only Capsules
  • No gelling agents
  • Improved physical and operational features to match the needs of the pharmaceutical industry

01

Dissolution profile

  • pH-independent performance 
  • Independent of ionic strength

02

Key advantages

  • Great visual appearance
  • Low-moisture content suitable for moisture-sensitive ingredients
  • Great machinability

03

More on Vcaps® plus

Vcaps® Enteric

 Right on target

Proven Properties

  • Intrinsically enteric capsule 
  • Improving tolerability of API’s that cause gastric-irritation 
  • API protection against degradation in the gastric environment
  • Achieving targeted release in the small intestine

01

In vitro dissolution test

  • Complies with pharmacopoeial requirements for delayed release
  • Robust enteric release 
  • Immediate and full disintegration at pH 6.8

02

Key advantages

  • Saves development time
  • No coating needed
  • High API protection

03

More on Vcaps® Enteric

Go to article: Home | Getting PersonalGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: In this issueGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: ContentsGo to article: Novo NordiskGo to article: NewsGo to article: PhoenixGo to article: The Pharma Industry BriefingGo to article: Nelson Lab Company InsightGo to article: Nelson LabsGo to article: Manufacturing personalised meds: what needs to change?Go to article: Molnar Company InsightGo to article: MolnarGo to article: Selling cells: the economics of CAR-T therapyGo to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Using AI to personalise drug combination therapyGo to article: NSFGo to article: Is the microbiome as important for precision medicine as genetics?Go to article: Nipro PharmaPackagingGo to article: A summer of manufacturing disasters for Chinese pharmaGo to article: CapsugelGo to article: EndocaGo to article: ContraFect’s Staph infection drug may succeed in trial but caveats remainGo to article: Dow Europe GmbH Company InsightGo to article: Dow Europe GmbHGo to article: Why are novel therapies for glioblastoma patients not gaining approvals?Go to article: Lubrizol Life SciencesGo to article: QualiMetriXGo to article: CAR-T approved in Europe but NICE verdict is divided: what happens next?Go to article: Palleos healthcare GmbH Go to article: Daiichi JitsugyoGo to article: EventsGo to article: Nemera Company InsightGo to article: Erdmann Design SwitzerlandGo to article: Next issueGo to article: NemeraGo to article: Plastiape Go to article: General Electric Healthcare